AIDS

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Retrieved on: 
Tuesday, March 26, 2019
Health, AIDS, Biotechnology, Clinical trials, Hospitals, Pharmaceutical, Bictegravir/emtricitabine/tenofovir alafenamide, Fixed dose combination, Specialty drugs, Biotechnology, Gilead Sciences, Life sciences, Integrase inhibitors

Biktarvy is the first HIV product that Gilead will launch and commercialize in Japan directly through its local subsidiary, Gilead Sciences K.K.

Key Points: 
  • Biktarvy is the first HIV product that Gilead will launch and commercialize in Japan directly through its local subsidiary, Gilead Sciences K.K.
  • In the United States, Biktarvy has a Boxed Warning in its product label regarding the risk of post-treatment acute exacerbation of hepatitis B.
  • In multiple clinical trials, Biktarvy has demonstrated high efficacy and a high barrier to resistance.
  • Biktarvy adds an important new treatment option to our portfolio of medicines for people living with HIV in Japan.

Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

Retrieved on: 
Tuesday, March 26, 2019
Health, AIDS, Biotechnology, Genetics, Infectious diseases, Research, Science, Branches of biology, Biology, Biochemistry, Gene delivery, Molecular biology, Biotechnology, Immune system, Immunology, Electroporation, Plasmid, Monoclonal antibody, Ichor

Ichor Medical Systems, Inc. (Ichor) announced today that it has entered into a collaboration and research license agreement with AstraZeneca (LSE, SSE, NYSE: AZN) for the development and clinical assessment of plasmid DNA constructs.

Key Points: 
  • Ichor Medical Systems, Inc. (Ichor) announced today that it has entered into a collaboration and research license agreement with AstraZeneca (LSE, SSE, NYSE: AZN) for the development and clinical assessment of plasmid DNA constructs.
  • The plasmids will encode monoclonal antibodies developed by AstraZeneca and will be delivered using Ichors TriGrid Delivery System .
  • Under the terms of the agreement, Ichor will receive upfront and annual payments along with development milestones.
  • Ichor Medical Systems investigational TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans.

Shaggy, Big Freedia Headline Saturday’s Florida AIDS Walk & Music Festival, on Track to Raise $1.5M

Retrieved on: 
Friday, March 22, 2019
Women, Entertainment, Music, Health, AIDS, Celebrity, General Entertainment, Infectious diseases, Pharmaceutical, Philanthropy, Events, Concerts, Other Philanthropy, Consumer, Foundation, Fund Raising, General Health, MEN, HIV/AIDS, Health, HIV/AIDS in the United States, HIV/AIDS activism, Pandemics, Articles, AIDS Healthcare Foundation, Epidemiology of HIV/AIDS, AIDS Walk, AIDS Services of Austin, HIV/AIDS in Australia

Funds raised from this event annually raises over $1 million to benefit 10 local non-profit organizations that are leading the fight against the local HIV/AIDS epidemic.

Key Points: 
  • Funds raised from this event annually raises over $1 million to benefit 10 local non-profit organizations that are leading the fight against the local HIV/AIDS epidemic.
  • Presented by AIDS Healthcare Foundation ( AHF ), the largest non-profit, global HIV/AIDS organization, the annual event attracts thousands of attendees from across the region.
  • Supported by an array of corporate partners including AHF Pharmacy, a national chain of pharmacies supporting U.S. & global HIV care, and Wells Fargo, the Florida AIDS Walk annually raises over $1 million in the fight against HIV/AIDS.
  • Now in its 14th year, Florida AIDS Walk & Music Festival has become a highly anticipated event aimed at increasing South Floridas awareness, prevention, and treatment efforts against the spread of HIV.

AHF to WHO: Action on Ebola Will Save Lives More than Words

Retrieved on: 
Wednesday, March 13, 2019
Health, AIDS, Infectious diseases, Public policy, Government, Other Government, Other Policy Issues, Animal diseases, Infectious diseases, Contents, West African Ebola virus epidemic, Ebola virus disease, Zoonoses

The recent statement by WHO may be well-intentioned, but whats needed right now are reforms that help the people who are dying every day, said AHF President Michael Weinstein.

Key Points: 
  • The recent statement by WHO may be well-intentioned, but whats needed right now are reforms that help the people who are dying every day, said AHF President Michael Weinstein.
  • With over 900 people having been infected with Ebola and almost 600 deaths since last August, AHF urges the international community to do more.
  • Just two weeks ago, two Ebola treatment centers were burned down in coordinated attacks that specifically targeted the response.
  • Statements and press releases only go so farit is time for real action to save lives.

Global AIDS Partnering Deals and Agreement Directory 2014-2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2019
Health, AIDS

The Global AIDS Partnering Terms and Agreements since 2014 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

Key Points: 
  • The Global AIDS Partnering Terms and Agreements since 2014 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
  • Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2014.
  • Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.
  • Global AIDS Partnering Terms and Agreements since 2014 report provides the reader with the following key benefits:
    Insight into key deal terms included in contracts, where disclosed
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005491/en/

Sustiva - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2019
Health, AIDS, Pharmaceutical, Drugs, Chemical compounds, Organic compounds, Hepatotoxins, Bristol-Myers Squibb, Business intelligence, Strategic management, Cyclopropanes, Efavirenz, SWOT analysis

The "Sustiva - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sustiva - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Sustiva Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.
  • In addition to this, the report also provides the SWOT analysis for Sustiva and emerging therapies in this space.

Norvir SEC - API Insight, 2019-2021: Historical & Forecasted Sales, Emerging Therapies and Key Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2019
Health, AIDS, Infectious diseases, Pharmaceutical, Chemistry, Organic chemistry, Physical sciences, Hepatotoxins, RTT, Ritonavir, Thiazoles, Ureas, Application programming interface

The "Norvir SEC - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Norvir SEC - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Norvir SEC - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
  • The report gives the clear idea on the country wise DMF filed by worldwide companies related to Norvir SEC.
  • The report also highlights the patent details of Norvir SEC.

Prezista - Drug Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2019
Health, AIDS, Pharmaceutical, Drug, Natural sciences, Articles, Pharmaceuticals policy, Life sciences, Pharmaceutical industry, Medicinal chemistry

The "Prezista - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prezista - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Prezista Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • A review of the Prezista, based on information derived from company and industry-specific sources
    Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification

Kivexa - Drug Insight, 2019-2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2019
Health, AIDS, Pharmaceutical, Strategic management, Business intelligence, Articles, Application programming interface, Technical communication, SWOT analysis, Pharmaceuticals policy, Market research

The "Kivexa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kivexa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Kivexa Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.
  • In addition to this, the report also provides the SWOT analysis for Kivexa and emerging therapies in this space.

CVS-Aetna Merger: Judge Grants AHF Amicus Petition Opposing Consolidation

Retrieved on: 
Thursday, March 7, 2019
Health, AIDS, Infectious diseases, Public policy, Government, Courts, Pharmaceutical, Professional services, Insurance, Health, AIDS Healthcare Foundation, Woonsocket, Rhode Island, Insurance companies, CVS Health, Aetna, AHF

After a judge halted the merger of CVS Health and Aetna in early December, citing anti-competitive concerns, AIDS Healthcare Foundation ( AHF ) applauded the judge and court for temporarily slowing the consolidation of the two health industry giants.

Key Points: 
  • After a judge halted the merger of CVS Health and Aetna in early December, citing anti-competitive concerns, AIDS Healthcare Foundation ( AHF ) applauded the judge and court for temporarily slowing the consolidation of the two health industry giants.
  • Today, AHF once again thanked Judge Richard Leon of the U.S. District Court for the District of Columbia for granting AHFs petition to participate as an amicus in the Aetna/CVS merger casea consolidation which AHF vehemently opposes, because it would be particularly bad for HIV patients.
  • AHF strongly believes the merger would have serious negative consequences for HIV patients and others with chronic health conditions.
  • In October, at a hearing held by New York regulators on the CVS-Aetna merger, AHF expressed its objections to the merger.